Skip to main content
Erschienen in: Clinical Drug Investigation 4/2008

01.04.2008 | Original Research Article

Non-Interventional Study Comparing Treatment Satisfaction in Patients Treated with Antihistamines

verfasst von: Dr Christine De Vos, Krassimir Mitchev, Marie-Etienne Pinelli, Marie-Paule Derde, Rossen Boev

Erschienen in: Clinical Drug Investigation | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

Background and objective: Allergic rhinitis and urticaria are common allergic disorders that may affect approximately 15% of people at some time in their lives. Antihistamines are the most widely used therapeutic interventions for these disorders but the newer generation agents have differing pharmacokinetic characteristics that may result in different patient satisfaction and preferences. The objective of this study was to investigate patients’ and physicians’ satisfaction with their current antihistamine treatment for allergic disease.
Methods: In an observational study, physicians in nine European countries completed questionnaires evaluating 7274 patients treated with an oral antihistamine. The satisfaction of patients and physicians with the efficacy and tolerability of treatment was rated on a visual analogue scale. In addition, the proportion of patients satisfied with treatment (overall satisfaction) and willing to continue treatment with the same antihistamine were assessed. Safety and tolerability data were also gathered.
Results: The results of this study indicate that modern antihistamines are generally considered effective and well tolerated by patients. In general, levocetirizine scored significantly higher in terms of perception of efficacy, tolerability and overall satisfaction. In terms of tolerability, three-quarters of patients were ‘very satisfied’ and a further fifth were moderately satisfied with levocetirizine and almost all (95%) were happy to continue treatment. Overall, the most commonly reported adverse event in this study was somnolence, a well known effect of antihistamines. The rate of somnolence in the levocetirizine group (3.8%) was similar to that for fexofenadine (both doses) and desloratadine, two products which are considered to be nonsedating antihistamines, and significantly less than half the rate for cetirizine.
Conclusion: Levocetirizine is considered an effective and well tolerated option for treating allergic disease by patients and physicians alike, particularly when the best available effectiveness and tolerability are required.
Literatur
1.
Zurück zum Zitat ISAAC. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 1998 Apr 25; 351(9111): 1225–32CrossRef ISAAC. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 1998 Apr 25; 351(9111): 1225–32CrossRef
2.
Zurück zum Zitat Mosges R, Klimek L. Today’s allergic rhinitis patients are different: new factors that may play a role. Allergy 2007: 62: 969–75PubMedCrossRef Mosges R, Klimek L. Today’s allergic rhinitis patients are different: new factors that may play a role. Allergy 2007: 62: 969–75PubMedCrossRef
3.
Zurück zum Zitat Maurer M, Zuberbier T. Undertreatment of rhinitis symptoms in Europe: findings from a cross-sectional questionnaire survey. Allergy 2007: 62: 1057–63PubMedCrossRef Maurer M, Zuberbier T. Undertreatment of rhinitis symptoms in Europe: findings from a cross-sectional questionnaire survey. Allergy 2007: 62: 1057–63PubMedCrossRef
4.
Zurück zum Zitat Gelfand EW. Pediatric allergic rhinitis: factors affecting treatment choice. Ear Nose Throat J 2005 Mar; 84(3): 163–8PubMed Gelfand EW. Pediatric allergic rhinitis: factors affecting treatment choice. Ear Nose Throat J 2005 Mar; 84(3): 163–8PubMed
5.
Zurück zum Zitat Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic Rhinitis and its Impact on Asthma (ARIA). J Allergy Clin Immunol 2001 Nov; 108(5 Suppl.): S147–334PubMedCrossRef Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic Rhinitis and its Impact on Asthma (ARIA). J Allergy Clin Immunol 2001 Nov; 108(5 Suppl.): S147–334PubMedCrossRef
6.
Zurück zum Zitat Humphreys F, Hunter JA. The characteristics of urticaria in 390 patients. Br J Dermatol 1998 Apr; 138(4): 635–8PubMedCrossRef Humphreys F, Hunter JA. The characteristics of urticaria in 390 patients. Br J Dermatol 1998 Apr; 138(4): 635–8PubMedCrossRef
7.
Zurück zum Zitat Ciprandi G, Cirillo I, Vizzaccaro A, et al. Seasonal and perennial allergic rhinitis: is this classification adherent to real life? Allergy 2005: 60: 882–7PubMedCrossRef Ciprandi G, Cirillo I, Vizzaccaro A, et al. Seasonal and perennial allergic rhinitis: is this classification adherent to real life? Allergy 2005: 60: 882–7PubMedCrossRef
8.
9.
Zurück zum Zitat Grob JJ, Gaudy-Marqueste C. Urticaria and quality of life. Clin Rev Allergy Immunol 2006 Feb; 30(1): 47–51PubMedCrossRef Grob JJ, Gaudy-Marqueste C. Urticaria and quality of life. Clin Rev Allergy Immunol 2006 Feb; 30(1): 47–51PubMedCrossRef
10.
Zurück zum Zitat Pfaar O, Wrede H, Barth C, et al. Levocetirizine in patients with chronic idiopathic urticaria: results of a multicenter clinical practice study. Int J Clin Pharmacol Ther 2006 Apr; 44(4): 191–2PubMed Pfaar O, Wrede H, Barth C, et al. Levocetirizine in patients with chronic idiopathic urticaria: results of a multicenter clinical practice study. Int J Clin Pharmacol Ther 2006 Apr; 44(4): 191–2PubMed
11.
Zurück zum Zitat Schoenwetter WF, Dupclay Jr L, Appajosyula S, et al. Economic impact and quality-of-life burden of allergic rhinitis. Curr Med Res Opin 2004 Mar; 20(3): 305–17PubMedCrossRef Schoenwetter WF, Dupclay Jr L, Appajosyula S, et al. Economic impact and quality-of-life burden of allergic rhinitis. Curr Med Res Opin 2004 Mar; 20(3): 305–17PubMedCrossRef
12.
Zurück zum Zitat Settipane RA. Complications of allergic rhinitis. Allergy Asthma Proc 1999 Jul–Aug; 20(4): 209–13PubMedCrossRef Settipane RA. Complications of allergic rhinitis. Allergy Asthma Proc 1999 Jul–Aug; 20(4): 209–13PubMedCrossRef
13.
Zurück zum Zitat Burge HA, Rogers CA. Outdoor allergens. Environ Health Perspect 2000 Aug; 108Suppl. 4: 653–9PubMed Burge HA, Rogers CA. Outdoor allergens. Environ Health Perspect 2000 Aug; 108Suppl. 4: 653–9PubMed
14.
Zurück zum Zitat Nash DB, Sullivan SD, Mackowiak J. Optimizing quality of care and cost effectiveness in treating allergic rhinitis in a managed care setting. Am J Manag Care 2000 Jan; 6(1 Suppl.): S3–15; quiz S19-20PubMed Nash DB, Sullivan SD, Mackowiak J. Optimizing quality of care and cost effectiveness in treating allergic rhinitis in a managed care setting. Am J Manag Care 2000 Jan; 6(1 Suppl.): S3–15; quiz S19-20PubMed
15.
Zurück zum Zitat Day JH, Horak F, Briscoe MP, et al. The role of allergen challenge chambers in the evaluation of anti-allergic medication: an international consensus paper. Clin Exp Allergy Rev 2006; 6: 31–59CrossRef Day JH, Horak F, Briscoe MP, et al. The role of allergen challenge chambers in the evaluation of anti-allergic medication: an international consensus paper. Clin Exp Allergy Rev 2006; 6: 31–59CrossRef
16.
Zurück zum Zitat Bousquet J, Lund VJ, van Cauwenberge P, et al. Implementation of guidelines for seasonal allergic rhinitis: a randomized controlled trial. Allergy 2003 Aug; 58: 733–41PubMedCrossRef Bousquet J, Lund VJ, van Cauwenberge P, et al. Implementation of guidelines for seasonal allergic rhinitis: a randomized controlled trial. Allergy 2003 Aug; 58: 733–41PubMedCrossRef
17.
Zurück zum Zitat Kapp A, Wedi B. Chronic urticaria: clinical aspects and focus on a new antihistamine, levocetirizine. J Drugs Dermatol 2004 Nov–Dec; 3(6): 632–9PubMed Kapp A, Wedi B. Chronic urticaria: clinical aspects and focus on a new antihistamine, levocetirizine. J Drugs Dermatol 2004 Nov–Dec; 3(6): 632–9PubMed
18.
Zurück zum Zitat Holgate ST, Canonica GW, Simons FE, et al. Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations. Clin Exp Allergy 2003 Sep; 33: 1305–24PubMedCrossRef Holgate ST, Canonica GW, Simons FE, et al. Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations. Clin Exp Allergy 2003 Sep; 33: 1305–24PubMedCrossRef
19.
Zurück zum Zitat Phipatanakul W. Allergic rhinoconjunctivitis: epidemiology. Immunol Allergy Clin North Am 2005 May; 25: 263–81PubMedCrossRef Phipatanakul W. Allergic rhinoconjunctivitis: epidemiology. Immunol Allergy Clin North Am 2005 May; 25: 263–81PubMedCrossRef
20.
Zurück zum Zitat Bauchau V, Durham SR. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. Allergy 2005 Mar; 60: 350–3PubMedCrossRef Bauchau V, Durham SR. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. Allergy 2005 Mar; 60: 350–3PubMedCrossRef
21.
Zurück zum Zitat Demoly P, Allaert FA, Lecasble M, et al. Validation of the classification of ARIA (Allergic Rhinitis and its Impact on Asthma). Allergy 2003 Jul; 58: 672–5PubMedCrossRef Demoly P, Allaert FA, Lecasble M, et al. Validation of the classification of ARIA (Allergic Rhinitis and its Impact on Asthma). Allergy 2003 Jul; 58: 672–5PubMedCrossRef
22.
Zurück zum Zitat Yates C. Parameters for the treatment of urticaria and angioedema. J Am Acad Nurse Pract 2002 Nov; 14(11): 478–83PubMedCrossRef Yates C. Parameters for the treatment of urticaria and angioedema. J Am Acad Nurse Pract 2002 Nov; 14(11): 478–83PubMedCrossRef
23.
Zurück zum Zitat Kozel MA, Sabroe RA. Chronic urticaria: aetiology, management and current and future treatment options. Drugs 2004; 64(22): 2515–36PubMedCrossRef Kozel MA, Sabroe RA. Chronic urticaria: aetiology, management and current and future treatment options. Drugs 2004; 64(22): 2515–36PubMedCrossRef
24.
Zurück zum Zitat Jorissen M, Bertrand B, Stiels B, et al. Levocetirizine as treatment for symptoms of seasonal allergic rhinitis. B-ENT 2006; 2: 55–62PubMed Jorissen M, Bertrand B, Stiels B, et al. Levocetirizine as treatment for symptoms of seasonal allergic rhinitis. B-ENT 2006; 2: 55–62PubMed
25.
Zurück zum Zitat Klimek L, Hundorf I. Levocetirizine in allergic diseases: an open multicentre practice study of efficacy and tolerability. Allergologie 2002; 25: S1–7 Klimek L, Hundorf I. Levocetirizine in allergic diseases: an open multicentre practice study of efficacy and tolerability. Allergologie 2002; 25: S1–7
26.
Zurück zum Zitat Klimek L, Wrede H, Schott BC, et al. Patients’ perception of the value of levocetirizine in allergic diseases: a multicentre observational study in Germany. Clin Drug Investig 2005; 25(9): 609–14PubMedCrossRef Klimek L, Wrede H, Schott BC, et al. Patients’ perception of the value of levocetirizine in allergic diseases: a multicentre observational study in Germany. Clin Drug Investig 2005; 25(9): 609–14PubMedCrossRef
27.
Zurück zum Zitat Kapp A, Pichler WJ. Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, parallel, multicenter study. Int J Dermatol 2006 Apr; 45: 469–74PubMedCrossRef Kapp A, Pichler WJ. Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, parallel, multicenter study. Int J Dermatol 2006 Apr; 45: 469–74PubMedCrossRef
28.
Zurück zum Zitat Devalia JL, De Vos C, Hanotte F, et al. A randomized, double-blind, crossover comparison among cetirizine, levocetirizine, and UCB 28557 on histamine-induced cutaneous responses in healthy adult volunteers. Allergy 2004 Jan; 56: 50–7CrossRef Devalia JL, De Vos C, Hanotte F, et al. A randomized, double-blind, crossover comparison among cetirizine, levocetirizine, and UCB 28557 on histamine-induced cutaneous responses in healthy adult volunteers. Allergy 2004 Jan; 56: 50–7CrossRef
29.
Zurück zum Zitat Grant JA, Riethuisen JM, Moulaert B, et al. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol 2002 Feb; 88(2): 190–7PubMedCrossRef Grant JA, Riethuisen JM, Moulaert B, et al. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol 2002 Feb; 88(2): 190–7PubMedCrossRef
30.
Zurück zum Zitat Purohit A, Melac M, Pauli G, et al. Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the skin. Br J Clin Pharmacol 2003 Oct; 56(4): 388–94PubMedCrossRef Purohit A, Melac M, Pauli G, et al. Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the skin. Br J Clin Pharmacol 2003 Oct; 56(4): 388–94PubMedCrossRef
31.
Zurück zum Zitat Bachert C, Bousquet J, Canonica GW, et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 2004 Oct; 114(4): 838–44PubMedCrossRef Bachert C, Bousquet J, Canonica GW, et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 2004 Oct; 114(4): 838–44PubMedCrossRef
Metadaten
Titel
Non-Interventional Study Comparing Treatment Satisfaction in Patients Treated with Antihistamines
verfasst von
Dr Christine De Vos
Krassimir Mitchev
Marie-Etienne Pinelli
Marie-Paule Derde
Rossen Boev
Publikationsdatum
01.04.2008
Verlag
Springer International Publishing
Erschienen in
Clinical Drug Investigation / Ausgabe 4/2008
Print ISSN: 1173-2563
Elektronische ISSN: 1179-1918
DOI
https://doi.org/10.2165/00044011-200828040-00003

Weitere Artikel der Ausgabe 4/2008

Clinical Drug Investigation 4/2008 Zur Ausgabe